High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer.

BACKGROUND AND PURPOSE Early detection of local recurrences following stereotactic ablative radiotherapy (SABR) for lung cancer may allow for curative salvage treatment, but recurrence can be difficult to distinguish from fibrosis. We studied the clinical performance of CT imaging high-risk features (HRFs) for detecting local recurrence. MATERIALS AND METHODS Patients treated with SABR for early stage lung cancer between 2003 and 2012 who developed pathology-proven local recurrence (n=12) were matched 1:2 to patients without recurrences (n=24), based on baseline factors. Serial CT images were assessed by blinded radiation oncologists. Previously reported HRFs were (1) enlarging opacity at primary site; (2) sequential enlarging opacity; (3) enlarging opacity after 12-months; (4) bulging margin; (5) loss of linear margin and (6) air bronchogram loss. RESULTS All HRFs were significantly associated with local recurrence (p<0.01), and one new HRF was identified: cranio-caudal growth (p<0.001). The best individual predictor of local recurrence was opacity enlargement after 12-months (100% sensitivity, 83% specificity, p<0.001). The odds of recurrence increased 4-fold for each additional HRF detected. The presence of ≥3 HRFs was highly sensitive and specific for recurrence (both >90%). CONCLUSION The systematic assessment of post-SABR CT images for HRFs enables the accurate prediction of local recurrence.

[1]  A. Bezjak,et al.  Surgical salvage following stereotactic body radiotherapy for early-stage NSCLC , 2012, European Respiratory Journal.

[2]  Suresh Senan,et al.  Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. , 2012, International journal of radiation oncology, biology, physics.

[3]  Andrea Bezjak,et al.  Stereotactic body radiation therapy for inoperable early stage lung cancer. , 2010, JAMA.

[4]  T. Araki,et al.  Computed tomography appearances of local recurrence after stereotactic body radiation therapy for stage I non-small-cell lung carcinoma , 2010, Japanese Journal of Radiology.

[5]  M. Tsao,et al.  Fine-needle aspiration biopsy versus core-needle biopsy in diagnosing lung cancer: a systematic review. , 2012, Current oncology.

[6]  W. Hsu,et al.  Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence , 2009, Thorax.

[7]  Joshua D. Lawson,et al.  A survey of stereotactic body radiotherapy use in the United States , 2011, Cancer.

[8]  E. Smit,et al.  Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. , 2008, International journal of radiation oncology, biology, physics.

[9]  Aaron Ward,et al.  Radiographic changes after lung stereotactic ablative radiotherapy (SABR)--can we distinguish recurrence from fibrosis? A systematic review of the literature. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  Steven F Petit,et al.  Reirradiation and stereotactic radiotherapy for tumors in the lung: dose summation and toxicity. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  E. Smit,et al.  Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Aaron D. Ward,et al.  CT image feature analysis in distinguishing radiation fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: a preliminary study , 2013, Medical Imaging.

[13]  Matthias Guckenberger,et al.  Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): results of a serial follow-up CT study. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  Heber MacMahon,et al.  The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. , 2012, The Journal of thoracic and cardiovascular surgery.

[15]  J. Mausner,et al.  Mausner and Bahn epidemiology : Introductory text , 1985 .

[16]  Hiroki Shirato,et al.  Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? , 2011, International journal of radiation oncology, biology, physics.

[17]  Suresh Senan,et al.  Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. , 2012, The Lancet. Oncology.

[18]  A. Yoshizawa,et al.  Salvage Lung Resection for Non-small Cell Lung Cancer After Stereotactic Body Radiotherapy in Initially Operable Patients , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  Lisa M. Schwartz,et al.  What do you mean, a spot?: A qualitative analysis of patients' reactions to discussions with their physicians about pulmonary nodules. , 2013, Chest.

[20]  M. Hiraoka,et al.  Evaluation of mass-like consolidation after stereotactic body radiation therapy for lung tumors , 2007, International Journal of Clinical Oncology.

[21]  C. Sima,et al.  Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. , 2013, The Journal of thoracic and cardiovascular surgery.

[22]  Max Dahele,et al.  Radiological Changes After Stereotactic Radiotherapy for Stage I Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  S. Senan,et al.  Radiological and clinical pneumonitis after stereotactic lung radiotherapy: a matched analysis of three-dimensional conformal and volumetric-modulated arc therapy techniques. , 2011, International journal of radiation oncology, biology, physics.

[24]  Ke Sheng,et al.  Computed tomography-based anatomic assessment overestimates local tumor recurrence in patients with mass-like consolidation after stereotactic body radiotherapy for early-stage non-small cell lung cancer. , 2012, International journal of radiation oncology, biology, physics.

[25]  L. Schwartz,et al.  When progressive disease does not mean treatment failure: reconsidering the criteria for progression. , 2012, Journal of the National Cancer Institute.

[26]  M. Kokubo,et al.  Surgical Treatment of Local Recurrence After Stereotactic Body Radiotherapy for Primary and Metastatic Lung Cancers , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  S. Senan,et al.  Lung density changes after stereotactic radiotherapy: a quantitative analysis in 50 patients. , 2011, International journal of radiation oncology, biology, physics.

[28]  I. Lax,et al.  Toxicity after reirradiation of pulmonary tumours with stereotactic body radiotherapy. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[29]  B. Yaremko,et al.  Stereotactic body radiotherapy versus surgery for medically operable Stage I non-small-cell lung cancer: a Markov model-based decision analysis. , 2011, International journal of radiation oncology, biology, physics.

[30]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[31]  Jose Belderbos,et al.  Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Makoto Kajihara,et al.  Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings , 2013, Annals of Nuclear Medicine.

[33]  E. Kunieda,et al.  Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer. , 2008, International journal of radiation oncology, biology, physics.

[34]  A. Ward,et al.  Distinguishing radiation fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: A quantitative analysis of CT density changes , 2013, Acta oncologica.